Syros Pharmaceuticals, Inc. SYRS · Stock Open Syros Pharmaceuticals, Inc. in new tab
Syros Pharmaceuticals, Inc. Analysis (SYRS)
Is Syros Pharmaceuticals, Inc. a good investment? Syros Pharmaceuticals, Inc. (SYRS) is currently trading at 0.000100 USD. Market analysts have a consensus price target of 8.75 USD. This suggests a potential upside from current levels.
Earnings Schedule: Syros Pharmaceuticals, Inc. is expected to release its next earnings report on July 29, 2026. The market consensus estimate for Forward EPS is -2.61.
Investor FAQ
Does Syros Pharmaceuticals, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Syros Pharmaceuticals, Inc.?
Syros Pharmaceuticals, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be July 29, 2026. The company currently has a trailing EPS of -3.07.
Company Profile
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
| Split Date | Split Ratio to 1 |
|---|---|
| Sept. 19, 2022 | 0.100000 |
Community Discussion